TRIPLE NEGATIVE BREAST NEOPLASMS
Clinical trials for TRIPLE NEGATIVE BREAST NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST NEOPLASMS trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising targeted therapy for tough breast cancer falls short in Late-Stage trial
Disease control TerminatedThis study tested whether adding the drug alpelisib to standard chemotherapy (nab-paclitaxel) could help people with advanced triple negative breast cancer that has specific genetic changes (PIK3CA mutation or PTEN loss). The trial enrolled 137 participants but was stopped early.…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called NUV-868, alone or with other cancer drugs (olaparib or enzalutamide), in 82 adults with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The trial was stopp…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
Experimental cancer pill tested in 23 patients, study halted early
Disease control TerminatedThis early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
Promising combo for aggressive breast cancer fails to finish
Disease control TerminatedThis study tested a drug called leronlimab combined with chemotherapy (carboplatin) in people with a specific type of advanced triple-negative breast cancer that has spread. Only 10 patients were enrolled before the trial was stopped early. The goal was to find a safe dose and se…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New combo therapy for advanced breast cancer shows early promise
Disease control TerminatedThis study tested a combination of two drugs—pembrolizumab (an immunotherapy) and mifepristone (a hormone blocker)—in people with advanced HER2-negative breast cancer. The goal was to see if the combination could shrink tumors. The study included 24 participants and was stopped e…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors (like ovarian, breast, lung, and others). The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 18, 2026 11:59 UTC